Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Pediatr Blood Cancer. 2020 Oct 7;68(1):e28719. doi: 10.1002/pbc.28719

FIGURE 3.

FIGURE 3

Mutational landscape and clinical outcomes of patients with T-ALL on DFCI 05-001 and 11-001. Summary of pathogenic mutations identified within Notch, PI3K, and Ras signaling pathways that are known to drive T-ALL and clinical outcome in patients treated on DFCI 05-001 and 11-001. ETP, Early T-cell Precursor; MRD, Minimal residual disease.